Cell Therapy News Volume 27.09 | May 25 2026

    0
    29






    2026-05-25 | CTN 27.09


    Cell Therapy News by STEMCELL Technologies
    Vol. 27.09 – 25 May, 2026
    TOP STORY

    Tumor Irradiation Promotes Antigen Dressing of Dendritic Cells to Enhance CAR T Cell Persistence and Efficacy in Lung Metastases

    Using syngeneic models of extensive metastatic lung adenocarcinoma and melanoma, investigators showed that 8 Gy of tumor irradiation significantly enhanced CAR T cell persistence in a manner critically dependent on dendritic cells.
    [Nature Cancer]

    Full Article
    Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies in this Inside Scientific webinar on June 18, in partnership with STEMCELL Technologies.
    PUBLICATIONSListed by the impact factor of the journal

    uPAR Is Highly Expressed in Recurrent Glioblastoma and Represents a Candidate CAR T Cell Target

    Scientists generated urokinase plasminogen activator receptor (uPAR)-specific CAR T cells, which demonstrated potent antitumor activity in recurrent glioblastoma patient–derived xenograft models.
    [Science Translational Medicine]

    Abstract | Press Release

    Armored Chimeric Antigen Receptor T Cell Therapy Targets Antigen-Heterogeneous Glioma

    Through head-to-head in vivo comparisons of potentially synergistic armor combinations, researchers demonstrated that T cells expressing a CAR plus IL-12 and the decoy-resistant form of IL-18 show strong efficacy against antigen-heterogeneous glioma in immunocompetent mice.
    [Cancer Research]

    Abstract

    IL-15 and IL-21 Synergy Improves Anti-Tumor Efficacy of iPSC-Derived Cytotoxic T Cells in Solid Tumors

    Researchers engineered iPSC-derived cytotoxic T cells transduced with a CAR and identified an optimal cytokine armoring strategy. Co-expression of interleukin (IL)-15 and IL-21 synergistically enhanceds STAT1 phosphorylation, leading to increased transcriptional activation of the chemokine receptor CXCR3.
    [Molecular Therapy]

    Full Article | Graphical Abstract

    Epitope Mapping of Humoral Immunogenicity of Orvacabtagene Autoleucel Shows an IgM Isotype Response with Minimal Impact on CAR T Cellular Kinetics

    Scientists monitored anti-CAR therapeutic domain-specific antibodies (ATAs) in 157 treated patients to assess treatment-related immunogenicity. The ATA status did not affect CAR T-cell expansion or patient survival outcomes, though reduced persistence was observed in ATA-positive patients.
    [Molecular Therapy]

    Abstract

    First-in-Human Study of FLT3 CAR-T Cell Therapy for Relapsed Acute Myeloid Leukemia

    In this first-in-human open-label study, autologous FLT3 CAR-T cells were delivered to two patients with relapsed and refractory FLT3+ acute myeloid leukemia.
    [NPJ Precision Oncology]

    Abstract
    REVIEWS

    Resetting Autoimmune Disease with CAR Cell Therapies

    CAR-expressing cells—initially developed and successfully used to treat certain cancers—are increasingly being developed to selectively deplete B cells and ‘reset’ the immune system in autoimmune diseases.
    [Nature Medicine]

    Abstract

    The In Vivo Revolution in CAR-T Therapy Medicinal Products: Challenges and Regulatory Prospects

    The emergence of in vivo CAR-T therapy medicinal products using viral vector or lipid nanoparticle platforms has provided a promising new direction by simplifying manufacturing, enhancing scalability, and lowering costs, though it may introduce elevated risks such as off-target effects and immunogenicity.
    [Signal Transduction and Targeted Therapy]

    Full Article

    Bioengineering CAR-T Cells to Function in Hostile Tumor Microenvironments

    This review synthesizes recent advances in CAR-T cell bioengineering aimed at overcoming physical barriers, immunosuppressive signaling, metabolic stress, and cellular exhaustion that characterize solid tumors, which are a leading cause of cancer-related mortality worldwide.
    [Trends in Biotechnology]

    Abstract
    INDUSTRY AND POLICY NEWS

    Matthew Larson Foundation Grant Helps Cancer Center Researcher Find New Ways to Treat Deadly Pediatric Brain Tumors

    Dr. Siddhartha Mitra recently received a three-year grant to develop CAR macrophages therapies to treat diffuse midline gliomas, a particularly deadly type of pediatric brain cancer.
    [University of Colorado Anschutz Cancer Center]

    Press Release

    CellChorus and Stanford Medicine Awarded NCI Grant to Develop AI-Driven Functional Assay Predicting CAR-T Response in Lymphoma Patients

    CellChorus, Inc. announced that the National Cancer Institute has awarded CellChorus® and Stanford Medicine a grant to profile cells from relapsed/refractory large B cell lymphoma patients after treatment with CAR-T cell therapy to develop a functional signature of response to therapy.
    [CellChorus, Inc.]

    Press Release
    FEATURED EVENT

    Frontiers in Cancer Immunotherapy

    June 22-23, 2026
    New York City, New York, United States

    > See All Events

    JOB OPPORTUNITIES

    Cell Therapy Specialist – Human Applications Lab

    St Jude Children’s Research Hospital – Memphis, Tennessee, United States

    PhD Student – Host-Pathogen Interactions

    Paul-Ehrlich-Institut – Langen, Germany

    Postdoctoral Research Fellow – Translational Research in Head and Neck Cancer

    Dana Farber Cancer Institute – Boston, Massachusetts, United States

    Postdoctoral Fellow – Pancreatic Cancer and Immune Eradication

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    Postdoctoral Research Fellow – Functional Genomics & CRISPR

    Fred Hutchinson Cancer Center – Seattle, Washington, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2